FDA panels plan September reviews of anemia drug safety

07/19/2007 | Boston Globe (tiered subscription model), The

FDA advisory panels plan to meet in September on anemia drugs made by Johnson & Johnson and Amgen to look at safety issues, including potential fatalities. One panel is to examine J&J's Procrit for patients with anemia caused by kidney failure, the other Amgen's Epogen and Aranesp, both for the same indication.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC